Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo

International Journal of Cancer

Volumn 127, Issue 12, 2010, Pages 2949-2958

  Wei, Gang ^a,b   Wang, Meifang ^a,b   Hyslop, Terry ^a,b   Wang, Ziqiu ^a,b   Carr, Brian I ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; ERK; HCC; Sorafenib; Vitamin K

Indexed keywords

4 AMINO 2 METHYL 1 NAPHTHOL; ACTIN; CASPASE; CASPASE 3; FARNOQUINONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHYTOMENADIONE; PROTEIN MCL 1; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RODENT; STAINING; TUMOR REGRESSION;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RAF KINASES; RATS; VITAMIN K;

EID: 78249244161     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25498     Document Type: Article

References (50)

1. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557 -76.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225 -49.
3. Altecruse SF, McGlynn KA, Reichman ME,. Hepatocellular carcinoma incidence, mortality and survival trends in the US from 1975 to 2005. J Clin Oncol 2009; 27: 1485 -91.
4. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintas-Cardama A, Small D, Cortes J, Andreeff M,. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 10: 184 -98.
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099 -109.
6. Flaherty KT,. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007; 7: 617 -26.
7. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27: 2823 -30.
8. Burris H, III, Rocha-Lima C,. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008; 13: 289 -98.
9. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F,. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008; 49: 2246 -55.
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378 -90.
11. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965 -72.
12. Krueger T, Westenfeld R, Schurgers L, Brandenburg V,. Coagulation meets calcification: the vitamin K system. Int J Artif Organs 2009; 32: 67 -74.
13. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S,. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol 2007; 39: 239 -47.
14. Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F, Takahashi T,. The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res 2008; 28: 45 -50.
15. Shibayama-Imazu T, Sakairi S, Watanabe A, Aiuchi T, Nakajo S, Nakaya K,. Vitamin K(2) selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from geranylgeraniol. J Cancer Res Clin Oncol 2003; 129: 1 -11.
16. Yokoyama T, Miyazawa K, Naito M, Toyotake J, Tauchi T, Itoh M, Yuo A, Hayashi Y, Georgescu MM, Kondo Y, Kondo S, Ohyashiki K,. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy 2008; 4: 629 -40.
17. Shah M, Stebbins JL, Dewing A, Qi J, Pellecchia M, Ronai ZA,. Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. Pigment Cell Melanoma Res 2009; 22: 799 -808.
18. Ma M, Qu XJ, Mu GY, Chen MH, Cheng YN, Kokudo N, Tang W, Cui SX,. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Chemotherapy 2009; 55: 28 -35.
19. Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A, Akahane T, Ogawa M, Nakai S, Deguchi A, Masaki T, Uchida N,. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 2005; 27: 505 -11.
20. Shiraki M, Shiraki Y, Aoki C, Miura M,. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: 515 -21.
21. Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T, Omata M,. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004; 40: 243 -51.
22. Matsumoto K, Okano J, Nagahara T, Murawaki Y,. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol 2006; 29: 1501 -8.
23. Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A, Akahane T, Ogawa M, Nakai S, Deguchi A, Masaki T, Uchida N,. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 2005; 27: 505 -11.
24. Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, Ohashi T, Kakumu S,. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 2073 -7.
25. Mizuta T, Ozaki I,. Clinical application of vitamin K for hepatocellular carcinoma. Clin Calcium 2007; 17: 1693 -9.
26. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S,. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol 2007; 39: 239 -47.
27. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W,. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 2002; 22: 3237 -46.
28. Luetteke NC, Michalopoulos GK,. Partial purification and characterization of a hepatocyte growth factor produced by rat hepatocellular carcinoma cells. Cancer Res 1985; 45: 6331 -7.
29. Chou TC,. The median-effect principle and the combination index for quantitation of synergism and antagonism. In:, Chou TC, Rideout DC, Eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press, 1991. 61 -102.
30. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27 -55.
31. Berenbaum MC,. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 1977; 28: 1 -18.
32. Kosakowska-Cholody T, Cholody WM, Hariprakasha HK, Monks A, Kar S, Wang S, Michejda CJ, Carr BI,. Growth inhibition of HCC cells in vitro and in vivo by the 8-methoxy analog of WMC79. Cancer Chemotherapy Pharmacol 2009; 63: 769 -78.
33. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263 -84.
34. Rahmani M, Davis EM, Bauer C, Dent P, Grant S,. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280: 35217 -27.
35. Herrant M, Jacquel A, Marchetti S, Belhac̈ne N, Colosetti P, Luciano F, Auberger P,. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23: 7863 -73.
36. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C,. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851 -8.
37. Gollob JA, Wilhelm S, Carter C, Kelley SL,. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392 -406.
38. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 7271 -8.
39. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505 -12.
40. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378 -90.
41. Hartmann JT, Haap M, Kopp HG, Lipp HP,. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470 -81.
42. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25 -34.
43. Sidovar MF, Kozlowski P, Lee JW, Collins MA, He Y, Graves LM,. Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J Biol Chem 2000; 275: 28688 -94.
44. Carr BI, Wei G, Wang M,. Vitamin k1 enhances sorafenib effects on HCC and induces apoptosis: a non-toxic prevention strategy. AACR 100th Annual Meeting, Denver, CO, 2009. 1319 p.
45. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M,. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22: 808 -18.
46. Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S,. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 2007; 13: 4280 -90.
47. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W,. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009; 220: 214 -21.
48. Elmore S,. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495 -516.
49. Kaufmann SH, Hengartner MO,. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001; 11: 526 -34.
50. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S,. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol 2007; 39: 239 -47.